Tasmanian Devil Antibodies Fight Cancer

The proteins could be the key to stopping the transmissible facial tumor disease that is threatening the species.

Written byJef Akst
| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share

Tasmanian devilFLICKR, CHEN WUComparing antibodies found in Tasmanian devils (Sarcophilus harrisii) with and without a devastating and contagious facial cancer, researchers found that the marsupials may have a natural immunity to the disease: those animals that had increased levels of the immunoglobulin IgM relative to IgG were less likely to have devil facial tumor disease (DFTD). The research was published last week (May 6) in Scientific Reports.

“We can deduce then that devils with higher natural antibody ratio are therefore less susceptible to the contagious cancer,” Beata Ujvari of Australia’s Deakin University said in a statement. “Anti-tumor vaccines that enhance the production of these natural antibodies, or direct treatment of the cancer with natural antibodies, could become a solution to help halt this disease. This process known as active immunotherapy, is becoming more and more accepted in treating human cancers, and we think it could be the magic bullet in saving the Tasmanian devils from extinction.”

The devils were listed as endangered by the Australian Government in 2009, and are also protected under the Tasmania’s Threatened Species Protection Act 1995 and the Red List of the International Union for the Conservation of ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • Jef (an unusual nickname for Jennifer) got her master’s degree from Indiana University in April 2009 studying the mating behavior of seahorses. After four years of diving off the Gulf Coast of Tampa and performing behavioral experiments at the Tennessee Aquarium in Chattanooga, she left research to pursue a career in science writing. As The Scientist's managing editor, Jef edited features and oversaw the production of the TS Digest and quarterly print magazine. In 2022, her feature on uterus transplantation earned first place in the trade category of the Awards for Excellence in Health Care Journalism. She is a member of the National Association of Science Writers.

    View Full Profile
Share
Illustration of a developing fetus surrounded by a clear fluid with a subtle yellow tinge, representing amniotic fluid.
January 2026

What Is the Amniotic Fluid Composed of?

The liquid world of fetal development provides a rich source of nutrition and protection tailored to meet the needs of the growing fetus.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies

Parse Logo

Parse Biosciences and Graph Therapeutics Partner to Build Large Functional Immune Perturbation Atlas

Sino Biological Logo

Sino Biological's Launch of SwiftFluo® TR-FRET Kits Pioneers a New Era in High-Throughout Kinase Inhibitor Screening

SPT Labtech Logo

SPT Labtech enables automated Twist Bioscience NGS library preparation workflows on SPT's firefly platform